Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database

Authors: Ximu Sun, Han Zhou, Yanming Li, Yanhui Luo, Qixiang Guo, Yixin Sun, Chenguang Jia, Bin Wang, Maoquan Qin, Peng Guo

Source: Future Journal of Pharmaceutical Sciences, Vol 11, Iss 1, Pp 1-12 (2025)

Subject Terms: IDH inhibitors, Enasidenib, Ivosidenib, Olutasidenib, FAERS, Pharmacovigilance, Therapeutics. Pharmacology, RM1-950, Pharmacy and materia medica, RS1-441

File Description: electronic resource

Relation: https://doaj.org/toc/2314-7253

Access URL: https://doaj.org/article/7cf8e751a5e442c5afc990ab7cf0cb77

Cutaneous manifestations in D-2-hydroxyglutaric aciduria type 2 and response to enasidenib therapy

Authors: Jennifer Roux, BS, Gabrielle Brody, MD, Brandie Metz, MD, Jingyun Gao, MD, Changrui Xiao, MD, Richard C. Chang, MD

Source: JAAD Case Reports, Vol 56, Iss , Pp 11-13 (2025)

Subject Terms: D-2-hydroxyglutaric aciduria, dermatitis, enasidenib, pediatric, Dermatology, RL1-803

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2352512624004181; https://doaj.org/toc/2352-5126

Access URL: https://doaj.org/article/957e1c58aedd4751ba1bd4cf071cb260

Differentiation Syndrome in a Patient With NSCLC Harboring IDH2 Mutation Treated With Enasidenib: Case Report

Authors: Bhoomika Sukhadia, MD, Dean Tan, BA, BS, Youjin Oh, MD, Zunairah Shah, MD, Young Kwang Chae, MD, MPH, MBA

Source: JTO Clinical and Research Reports, Vol 5, Iss 10, Pp 100520- (2024)

Subject Terms: Enasidenib, IDH2 inhibitor, Differentiation syndrome, Non–small cell lung cancer, Case Report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364323000590; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/19831a8ca6a14d10bc58dd48f0004a12

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcomaResearch in context

Authors: Verónica Rey, Juan Tornín, Juan Jose Alba-Linares, Cristina Robledo, Dzohara Murillo, Aida Rodríguez, Borja Gallego, Carmen Huergo, Cristina Viera, Alejandro Braña, Aurora Astudillo, Dominique Heymann, Karoly Szuhai, Judith V.M.G. Bovée, Agustín F. Fernández, Mario F. Fraga, Javier Alonso, René Rodríguez

Source: EBioMedicine, Vol 102, Iss , Pp 105090- (2024)

Subject Terms: Chondrosarcoma, Enasidenib, IDH2, Patient-derived models, Personalized medicine, Medicine, Medicine (General), R5-920

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2352396424001257; https://doaj.org/toc/2352-3964

Access URL: https://doaj.org/article/a9bcedfaab4940eeb62fdf6d5e65245e

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis

Authors: Xiu Chen, Hongyun Xing, Xiaolu Xie, Liqiu Kou, Jun Li, Yaling Li

Source: Clinical Epigenetics, Vol 15, Iss 1, Pp 1-12 (2023)

Subject Terms: IDH inhibitors, Ivosidenib, Enasidenib, Acute myeloid leukemia, Meta-analysis, Medicine, Genetics, QH426-470

File Description: electronic resource

Relation: https://doaj.org/toc/1868-7083

Access URL: https://doaj.org/article/1fb8418815594aef803ff55a77292a12

Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents

Authors: Ahmed F. Khalil, Tarek F. El-Moselhy, Eman A. El-Bastawissy, Rasha Abdelhady, Nancy S. Younis, Mervat H. El-Hamamsy

Source: Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 38, Iss 1 (2023)

Subject Terms: Synthesis, triazine, hydrazine, IDH2, enasidenib, leukaemia, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://doaj.org/toc/1475-6366; https://doaj.org/toc/1475-6374

Access URL: https://doaj.org/article/285de629095c4ab3a670666486c70121

The beginning of a new therapeutic era in acute myeloid leukemia

Authors: Christian Récher

Source: eJHaem, Vol 2, Iss 4, Pp 823-833 (2021)

Subject Terms: acute myeloid leukemia, CPX‐351, enasidenib, FLT3 inhibitors, gemtuzumab ozogamycin, gilteritinib, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/2688-6146

Access URL: https://doaj.org/article/ae0da44567f84bcd949c634bffe9d538

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis

Authors: Stéphane deBotton, Joseph M. Brandwein, Andrew H. Wei, Arnaud Pigneux, Bruno Quesnel, Xavier Thomas, Ollivier Legrand, Christian Recher, Sylvain Chantepie, Mathilde Hunault‐Berger, Nicolas Boissel, Salem A. Nehme, Mark G. Frattini, Alessandra Tosolini, Roland Marion‐Gallois, Jixian J. Wang, Chris Cameron, Muhaimen Siddiqui, Brian Hutton, Gary Milkovich, Eytan M. Stein

Source: Cancer Medicine, Vol 10, Iss 18, Pp 6336-6343 (2021)

Subject Terms: acute myeloid leukemia, enasidenib, IDH2 mutations, overall survival, standard of care, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/a8b6b60e03224a14a77e3d31e872ffc8

Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome

Authors: Pavan Annamaraju, Swathi Gopishetty, Naga Goparaju, Matthew Beasey, Vamsi Kota, Achuta K. Guddati

Source: Case Reports in Oncology, Vol 13, Iss 2, Pp 583-587 (2020)

Subject Terms: acute myeloid leukemia, chemotherapy, drug therapy, enasidenib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.karger.com/Article/FullText/507613; https://doaj.org/toc/1662-6575

Access URL: https://doaj.org/article/a98464ff85ad428ea0c90ef86216f711

The Time Has Come for Targeted Therapies for AML: Lights and Shadows

Authors: Alessandro Fiorentini, Debora Capelli, Francesco Saraceni, Diego Menotti, Antonella Poloni, Attilio Olivieri

Source: Oncology and Therapy, Vol 8, Iss 1, Pp 13-32 (2020)

Subject Terms: Acute myeloid leukemia, Enasidenib, Gemtuzumab ozogamicin, Genetoclax, Gilteritinib, Glasdegib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2366-1070; https://doaj.org/toc/2366-1089

Access URL: https://doaj.org/article/8577bf14a4e34c9f8e4900bdd2651da6

Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment

Authors: Reed DR, Elsarrag RZ, Morris AL, Keng MK

Source: Cancer Management and Research, Vol Volume 11, Pp 8073-8080 (2019)

Subject Terms: isocitrate dehydrogenase (IDH) 2, relapsed/refractory (R/R) acute myeloid leukemia (AML), enasidenib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.dovepress.com/enasidenib-in-acute-myeloid-leukemia-clinical-development-and-perspect-peer-reviewed-article-CMAR; https://doaj.org/toc/1179-1322

Access URL: https://doaj.org/article/0ac22375ab1d46d98324f5388e457b03

Enasidenib‐induced Sweet syndrome with differentiation syndrome

Authors: Amr Mohamed

Source: Clinical Case Reports, Vol 9, Iss 5, Pp n/a-n/a (2021)

Subject Terms: Differentiation syndrome, enasidenib, Sweet syndrome, Medicine, Medicine (General), R5-920

File Description: electronic resource

Relation: https://doaj.org/toc/2050-0904

Access URL: https://doaj.org/article/a57677562bd243f6912c312bdf2e6685

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

Authors: Claudio Cerchione, Alessandra Romano, Naval Daver, Courtney DiNardo, Elias Joseph Jabbour, Marina Konopleva, Farhad Ravandi-Kashani, Tapan Kadia, Maria Paola Martelli, Alessandro Isidori, Giovanni Martinelli, Hagop Kantarjian

Source: Frontiers in Oncology, Vol 11 (2021)

Subject Terms: acute myeloid leukemia, AML, enasidenib, IDH, isocitrate dehydrogenase, ivosidenib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2021.639387/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/a114ff99cd32458eb7e711de3f37c1cd

Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment

Authors: Li Y, Connarn JN, Chen J, Tong Z, Palmisano M, Zhou S

Source: Clinical Pharmacology: Advances and Applications, Vol Volume 11, Pp 39-50 (2019)

Subject Terms: Enasidenib, modeling and simulation, CYP3A induction, 4β-hydroxycholesterol, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: https://www.dovepress.com/modeling-and-simulation-of-the-endogenous-cyp3a-induction-marker-4beta-peer-reviewed-article-CPAA; https://doaj.org/toc/1179-1438

Access URL: https://doaj.org/article/89d8c3d7c95e4600bcda76ac235acd0c

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics

Authors: Danielle Golub, Nishanth Iyengar, Siddhant Dogra, Taylor Wong, Devin Bready, Karen Tang, Aram S. Modrek, Dimitris G. Placantonakis

Source: Frontiers in Oncology, Vol 9 (2019)

Subject Terms: acute myeloid leukemia, enasidenib, glioma, IDH, isocitrate dehydrogenase, ivosidenib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/article/10.3389/fonc.2019.00417/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/f275d4fdff3c4d98b3f8c34da88e089d

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.